Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy

American Journal of Transplantation

Volumn 10, Issue 12, 2010, Pages 2604-2614

  Brouard, S ^a   Puig Pey, I ^b   Lozano, J J ^c   Pallier, A ^a   Braud, C ^d   Giral, M ^a,e   Guillet, M ^d   Londono M C ^b   Oppenheimer, F ^b   Campistol, J M ^b   Soulillou, J P ^a,e,f   Sanchez Fueyo, A ^b  

^a INSERM   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d TcLand Expression   (France)

^e HÔTEL DIEU   (France)

^f UNIVERSITÉ DE NANTES   (France)

Author keywords

Calcineurin inhibitors; gene expression; immunosuppression; kidney transplantation; sirolimus; tolerance

Indexed keywords

AKR1C1 PROTEIN; AKR1C2 PROTEIN; AURORA A KINASE; BASILIXIMAB; BUB1B PROTEIN; CADHERIN 2; CD4 ANTIGEN; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 2; CHECK1 PROTEIN; COMPLEMENT COMPONENT C1S; CREATININE; CYCLOSPORIN A; DEPDC1 PROTEIN; GAGE PROTEIN; HBB PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LTB4DH PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MS4A1 PROTEIN; MTHFD2 PROTEIN; NCAPH PROTEIN; NR2F1 PROTEIN; OKT 3; PREDNISONE; RAPAMYCIN; SOMATOMEDIN BINDING PROTEIN 3; TACROLIMUS; TRANSCRIPTION FACTOR ELF 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CD4+ CD25+ T LYMPHOCYTE; CELL LINEAGE; CELL SPECIFICITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GLOMERULOPATHY; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEMORY T LYMPHOCYTE; MICROARRAY ANALYSIS; MONOCYTE; MONOTHERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEINURIA; RNA EXTRACTION; T LYMPHOCYTE; TRANSPLANT GLOMERULOPATHY;

CD4 LYMPHOCYTE COUNT; CYCLOSPORINE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PHENOTYPE; SIROLIMUS; T-LYMPHOCYTES;

EID: 78649836813     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03302.x     Document Type: Article

References (52)

1. Grinyo JM, Cruzado JM,. Mycophenolate mofetil and calcineurin-inhibitor reduction: Recent progress. Am J Transplant 2009; 9: 2447-2452.
2. Clipstone NA, Crabtree GR,. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-697.
3. Racusen LC, Solez K, Colvin R,. Fibrosis and atrophy in the renal allograft: Interim report and new directions. Am J Transplant 2002; 2: 203-206.
4. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB,. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590. (Pubitemid 34438820)
5. Stallone G, Infante B, Schena A, et al,. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755-3762.
6. Watson CJ, Firth J, Williams PF, et al,. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496-2503.
7. Mondino A, Mueller DL,. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007; 19: 162-172.
8. Weichhart T, Costantino G, Poglitsch M, et al,. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565-577.
9. Muller-Steinhardt M, Wortmeier K, Fricke L, Ebel B, Hartel C,. The pharmacodynamic effect of sirolimus: Individual variation of cytokine mRNA expression profiles in human whole blood samples. Immunobiology 2009; 214: 17-26.
10. Woltman AM, De Fijter JW, Kamerling SW, et al,. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98: 174-180.
11. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW,. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228-236.
12. Segundo DS, Ruiz JC, Izquierdo M, et al,. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4 + CD25 + FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550-557.
13. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB,. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722-1732.
14. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW,. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018-7031.
15. Thomson AW, Turnquist HR, Raimondi G,. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324-337.
16. Reichardt W, Durr C, Von Elverfeldt D, et al,. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol 2008; 181: 4770-4779.
17. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M,. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-1572.
18. Kahan BD,. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
19. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
20. Weiner SM, Sellin L, Vonend O, et al,. Pneumonitis associated with sirolimus: Clinical characteristics, risk factors and outcome-a single-centre experience and review of the literature. Nephrol Dial Transplant 2007; 22: 3631-3637.
21. Thaunat O, Beaumont C, Chatenoud L, et al,. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005; 80: 1212-1219.
22. Tomlanovich SJ, Vincenti F,. Sirolimus: Defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol 2007; 2: 198-199.
23. Buhaescu I, Izzedine H, Covic A,. Sirolimus-challenging current perspectives. Ther Drug Monit 2006; 28: 577-584.
24. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB,. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298-1302.
25. Araki K, Turner AP, Shaffer VO, et al,. mTOR regulates memory CD8 T cell differentiation. Nature 2009; 460: 108-112.
26. Roussey-Kesler G, Giral M, Moreau A, et al,. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736-746.
27. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
28. Edgar R, Domrachev M, Lash AE,. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucl Acids Res 2002; 30: 207-210.
29. Subramanian A, Tamayo P, Mootha VK, et al,. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
30. Mootha VK, Lindgren CM, Eriksson KF, et al,. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics 2003; 34: 267-273.
31. Watkins NA, Gusnanto A, De Bono B, et al,. A HaemAtlas: Characterizing gene expression in differentiated human blood cells. Blood 2009; 113: e1-e9.
32. Brouard S, Mansfield E, Braud C, et al,. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448-15453.
33. Tibshirani R, Hastie T, Narasimhan B, Chu G,. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 6567-6572.
34. Ashton-Chess J, Mai HL, Jovanovic V, et al,. Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney Intern 77: 880-890.
35. Ashton-Chess J, Dugast E, Colvin RB, et al,. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009; 20: 1113-1122.
36. Braudeau C, Ashton-Chess J, Giral M, et al,. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 2008; 86: 130-136.
37. Ashton-Chess J, Giral M, Mengel M, et al,. Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J Am Soc Nephrol 2008; 19: 1116-1127.
38. Vasconcellos LM, Schachter AD, Zheng XX, et al,. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66: 562-566.
39. Shoker A, George D, Yang H, Baltzan M,. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. Transplantation 2000; 70: 497-505.
40. Dugre FJ, Gaudreau S, Belles-Isles M, Houde I, Roy R,. Cytokine and cytotoxic molecule gene expression determined in peripheral blood mononuclear cells in the diagnosis of acute renal rejection. Transplantation 2000; 70: 1074-1080.
41. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL,. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant 2008; 8: 1652-1661.
42. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG,. Rapamycin promotes expansion of functional CD4+CD25+FOXP3 +regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338-8347.
43. Noris M, Casiraghi F, Todeschini M, et al,. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007-1018.
44. Mariotti J, Foley J, Jung U, et al,. Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol 2008; 180: 89-105.
45. Hackstein H, Taner T, Zahorchak AF, et al,. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-4463.
46. Schmitz F, Heit A, Dreher S, et al,. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 2008; 38: 2981-2992.
47. Yang CS, Song CH, Lee JS, et al,. Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages. Cell Microbiol 2006; 8: 1158-1171.
48. Strom TB, Koulmanda M,. Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 2009; 20: 1677-1680.
49. Chen L, Ahmed E, Wang T, et al,. TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol 2009; 182: 6217-6225.
50. Mitchell P, Afzali B, Lombardi G, Lechler RI,. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 326-331.
51. Newell KA, Asare A, Kirk AD, et al,. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120 (6): 1836-1847.
52. Sagoo P, Perucha E, Sawitzki B, et al,. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 1848-1861.